ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

Traditionally, scientists have used 2D cell cultures as in vitro models in drug screening studies due to their simplicity and scalability. However, 2D cell models do not recapitulate the complexity of ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.

Single-cell sequencing reveals cellular heterogeneity within models, while advanced imaging captures dynamic processes in living organoids. These tools, combined with rigorous validity assessment, ...

Early detection of safety liabilities of new therapies is a critical biopharmaceutical challenge. Addressing this challenge could significantly advance drug discovery. Advanced human cell models, ...

State-of-the-art AI model accurately predicting unseen biological experiments X-Cell is trained on X-Atlas/Pisces, the largest and most context-diverse genome-wide perturbation dataset ever reported ...